Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.
Preoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.
For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...
Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.
Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...
Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...
Taiwan: A recent cohort study has highlighted the potential benefits of combining glucagon-like peptide-1 receptor agonists ...
Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 ...
HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results